Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
Clinical Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), with particular research interests in diabetic eye disease and age-related macular degeneration.
Alongside this, she works on two large randomised controlled trials: ASCEND and REVEAL.
ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes.
REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease.
Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
-
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Journal article
Judge PK. et al, (2024), Nephrol Dial Transplant
-
Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial.
Journal article
Sammons EL. et al, (2024), BMC Ophthalmol, 24
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
-
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Journal article
Judge P. et al, (2024), Nephrology Dialysis Transplantation
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Nephrol Dial Transplant